Slide 1: Second Quarter 2024 Financial Results and Corporate Update
Immunic Therapeutics Second Quarter 2024 Financial Results and Corporate Update NASDAQ: IMUX | August 8, 2024
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Slide 3: Agenda
Agenda Second Quarter 2024 Financial Results and Corporate Update 01 Second Quarter 2024 and Subsequent Highlights 04 Q&A Session 02 Financial and Operating Results 05 Summary and Highlights 03 Anticipated Clinical Milestones 3 | © Immunic, Inc. | Aug/08/2024
Slide 4: Second Quarter 2024 and Subsequent Highlights
01 Second Quarter 2024 and Subsequent Highlights
Slide 5: April: Hosted In-Person Multiple Sclerosis R&D Day in San Francisco
April: Hosted In-Person Multiple Sclerosis R&D Day in San Francisco Could Vidofludimus Calcium be the First Neuroprotective Treatment Option for Multiple Sclerosis? Immunic speakers: § Daniel Vitt, PhD, CEO & President § Hella Kohlhof, PhD, CSO § Andreas Muehler, MD, CMO Attending expert: § Zuoming
Slide 6: April: Publication in Neurology Neuroimmunology & Neuroinflammation
April: Publication in Neurology® Neuroimmunology & Neuroinflammation, an Official Journal of the American Academy of Neurology Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis § “Safety and Dose-Response of Vidofludimus Calcium in Relapsing
Slide 7: May: Presented Data From Phase 2 CALLIPER Trial and Phase 1b Trial of IMU-856
May: Presented Data From Phase 2 CALLIPER Trial of Vidofludimus Calcium and Phase 1b Trial of IMU-856 at Scientific Conferences Digestive Disease Week XXIII National Congress CMSC 38th (DDW) 2024 of Neurology Annual Meeting § May 18-21 in Washington, D.C. § May 30 - June 2 in Golden Sands, Bulgaria
Slide 8: July: Strengthened Management Team
July: Strengthened Management Team Jason Tardio Appointed Werner Gladdines Promoted Chief Operating Officer and President Chief Development Officer § Brings extensive § Joined Immunic in multiple sclerosis drug January 2021; has commercialization held positions of experience to Immunic increasing re
Slide 9: July: Strengthened Board of Directors with Senior Pharmaceutical Executive
July: Strengthened Board of Directors with Senior Pharmaceutical Executive and Thought Leader in Brain Health Simona Skerjanec, M.Pharm, MBA § Thought-leader in brain health with decades of experience in drug development and commercialization in the United States and internationally § Has led resear
Slide 10: Financial and Operating Results
02 Financial and Operating Results
Slide 11: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Six Months Ended June 30, Ended June 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 18,323 $ 21,172 $ 37,059 $ 44,135 General and administrative 4,491 3,
Slide 12: Anticipated Clinical Milestones
03 Anticipated Clinical Milestones
Slide 13: Several Clinical Value Inflection Points Ahead
Several Clinical Value Inflection Points Ahead IMU-838 § Top-line data from phase 2 CALLIPER trial in PMS expected in April 2025 § Interim, non-binding futility analysis of phase IMU-838 3 ENSURE program expected in Q4/2024 in RMS § Completion of first phase 3 ENSURE trial anticipated in Q2/2026, se
Slide 14: Q&A Session
04 Q&A Session
Slide 15: Summary and Highlights
05 Summary and Highlights
Slide 16: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Relapsing Multiple Sclerosis (RMS) – ENSURE Trials Vidofludimus Calcium Progressive Multiple Sclerosis (PMS) – CALLIPER Trial (IMU-838) Ulcerative Colitis (UC
Slide 17: Thank You!
Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Vice President Investor Relations & Communications Immunic Australia Pty. Ltd. Melbourne Phone: +49-89-2080477-09 Australia Email: ir@imux.co